ÖÐÎÄÃû³Æ£ºÍÿ¹CBL (phospho-Tyr700)¶à¿Ë¡¿¹Ìå
±ð Ãû£º CBL2; NSLL; C-CBL; RNF55; FRA11B
Ïà¹ØÀà±ð£º Ò»¿¹
´¢ ´æ£º Àä¶³£¨-20¡æ£© ±Ü¹â
ËÞ Ö÷£º Rabbit
¿¹ Ô£º CBL (phospho-Tyr700)
·´Ó¦ÖÖÊô£º Human, Mouse, Rat
±ê ¼Ç Î Unconjugate
¿Ë¡ÀàÐÍ£º rabbit polyclonal
¼¼Êõ¹æ¸ñ
|
Background: |
Participates in signal transduction in hematopoietic cells. Adapter protein that functions as a negative regulator of many signaling pathways that start from receptors at the cell surface. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including PDGFA, EGF and CSF1, and terminates signaling. |
|
Applications: |
WB, IHC, IF |
|
Name of antibody: |
CBL (phospho-Tyr700) |
|
Immunogen: |
Synthetic peptide of human CBL (phospho-Tyr700) |
|
Full name: |
Cbl proto-oncogene, E3 ubiquitin protein ligase (phospho-Tyr700) |
|
Synonyms£º |
CBL2; NSLL; C-CBL; RNF55; FRA11B |
|
SwissProt: |
P22681 |
|
IHC positive control: |
Human breast carcinoma |
|
IHC Recommend dilution: |
50-100 |
|
WB Predicted band size: |
120 kDa |
|
WB Positive control: |
HT29 cells treated with UV |
|
WB Recommended dilution: |
500-1000 |
|
IF Positive control: |
Hela cells |
|
IF Recommended dilution |
100-200 |



¹ºÎï³µ
°ïÖú
021-54845833/15800441009
